PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.79%
Negative EBIT growth while AGEN is at 15.33%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-30.79%
Negative operating income growth while AGEN is at 12.69%. Joel Greenblatt would press for urgent turnaround measures.
-31.28%
Negative net income growth while AGEN stands at 10.19%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-21.00%
Negative EPS growth while AGEN is at 12.10%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.22%
Negative diluted EPS growth while AGEN is at 12.10%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
7.78%
Share count expansion well above AGEN's 2.22%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.68%
Diluted share count expanding well above AGEN's 2.22%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-4.39%
Negative OCF growth while AGEN is at 22.18%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-4.24%
Negative FCF growth while AGEN is at 22.56%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7210.53%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
76.96%
Positive OCF/share growth while AGEN is negative. John Neff might see a comparative advantage in operational cash viability.
70.68%
3Y OCF/share CAGR above 1.5x AGEN's 26.08%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-11609.25%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
81.05%
Positive 5Y CAGR while AGEN is negative. John Neff might view this as a strong mid-term relative advantage.
70.82%
3Y net income/share CAGR above 1.5x AGEN's 29.33%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
881.79%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-26.92%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-79.64%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-41.29%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-11.75%
We’re deleveraging while AGEN stands at 5.38%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
20.45%
R&D growth drastically higher vs. AGEN's 1.96%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
69.30%
SG&A growth well above AGEN's 0.94%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.